Amphetamine Aspartate

CHEMBL1200377 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

403.5 g/mol

LogP

—

Phase

4

The aspartate salt of amphetamine, used as one component in mixed amphetamine salt formulations. It contributes to the stimulant effects that improve attention and reduce hyperactivity in ADHD.

Masse moléculaire

403,5000 g/mol

TPSA

153,00 Å²

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O

InChI

InChI=1S/C9H13N.C4H7NO4/c1-8(10)7-9-5-3-2-4-6-9;5-2(4(8)9)1-3(6)7/h2-6,8H,7,10H2,1H3;2H,1,5H2,(H,6,7)(H,8,9)

Molecular Formula

C22H33N3O4

HBD / HBA

5 / 7

Liaisons Rotatives

7

Atomes Lourds

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The aspartate salt of amphetamine, used as one component in mixed amphetamine salt formulations. It contributes to the stimulant effects that improve attention and reduce hyperactivity in ADHD.

Yes, Amphetamine Aspartate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200377. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9801310. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Amphetamine Aspartate sur PillFYI

Structure

Données Clés

Formule: C22H33N3O4
Synonymes: 11

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.